In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Erytech Pharma SA (ERYP). The company’s shares closed last Monday at $5.28, close to its 52-week low of $5.20.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 0.7% and a 41.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Erytech Pharma SA with a $13 average price target, implying a 146.1% upside from current levels. In a report issued on September 5, JMP Securities also initiated coverage with a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.65 and a one-year low of $5.20. Currently, Erytech Pharma SA has an average volume of 387.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
